Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 02:20:46 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
Next:Flight attendant reveals why plane passengers should NEVER fall asleep before take off
You may also like
- UN Security Council rejects Russia
- Husband of Florida woman missing in Spain is charged with her disappearance
- ABC News president Kim Godwin steps down
- The night that bra
- Israeli army says it kills over 130 militants in E. Rafah
- Double European weightlifting champion Pielieshenko killed in Ukraine war
- Kyle Larson and Denny Hamlin, the dominant NASCAR Cup Series drivers, could have a blooming rivalry
- Liam Gallagher rents swanky £17,000
- Wildfires sweep across Finland, straining rescue services